Developing a new class of biologics to break the cycle of injury and inflammation

AIRWAY THERAPEUTICS

Airway Therapeutics is developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.

learn more

content01

zelpultide alfa(AT-100)

zelpultide alfa (AT-100) is the novel recombinant human protein rhSP-D – an engineered version of the endogenous protein hSP-D – that reduces inflammation and infection while modulating the immune response to break the cycle of injury and inflammation.

learn more

WHAT IS BPD?

Bronchopulmonary dysplasia is a ventilation and infection-induced respiratory disease with 200,000 very preterm infants at risk in the U.S. and Europe each year. Globally, about 2.5 million very pre-term infants are at-risk annually. BPD creates long-term lung damage that can lead to pro-longed NICU stays, a range of co-morbidities, lifelong chronic consequences and even death.

learn more

content01

CONTACT


For members of the scientific/medical and investment communities,
contact us at the link below by filling out our inquiry form.

contact us